Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of STN1013800 (Oxymetazoline) in Healthy Adults
NCT06911216Phase 1Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Mar 2025
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of oxymetazoline in acquired blepharoptosis, sponsored by Santen Pharmaceutical. Primary endpoints: Maximum Plasma Concentration at Day 7, Minimum Plasma Concentration at Day 7 and 6 more. Started Mar 2025; status: completed.
02
Drugs
oxymetazoline
03
Conditions
acquired blepharoptosis
Beyond the preview
Go deeper on NCT06911216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06911216.